Medical technology company KORU Medical Systems Inc (NASDAQ:KRMD) announced on Wednesday a new agreement to develop and seek regulatory approval of its Freedom Infusion System with a subcutaneous immunoglobulin therapy (SCIg) prefilled syringe.

This agreement with an undisclosed pharmaceutical manufacturer of SCIg provides for KORU Medical to develop an adaptation to its Freedom Infusion System to enable an SCIg prefilled syringe to be usable by patients globally, and to seek regulatory authorisation for adaptation.

Terms of the agreement were not disclosed.

"The Freedom Infusion System is the only infusion system approved for prefilled syringes, and we are excited by the opportunity to expand the number of prefilled subcutaneous therapies that are FDA approved for our innovative infusion system," said Linda Tharby, KORU Medical's president and CEO.

KORU Medical develops, manufactures and commercialises subcutaneous drug delivery systems. Its Freedom Infusion System currently includes the FREEDOM60 and FreedomEdge Syringe Infusion Drivers, Precision Flow Rate Tubing and HIgH-Flo Subcutaneous Safety Needle Sets. These devices are used for infusions administered in the home and alternate care settings.